WPC
ABMD

Wedmont Private Capital’s Abiomed Inc ABMD Stock Holding History

Wedmont Private Capital’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,552
Closed -$381K – 474
2022
Q3 		$381K Buy
1,552
+307
+25% +$82.9K 0.08% 203
2022
Q2 		$308K Sell
1,245
-92
-7% -$24.8K 0.07% 229
2022
Q1 		$435K Buy
+1,337
New +$412K 0.1% 162

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Wedmont Private Capital's ABMD Position: Q4 2022 in Review

Wedmont Private Capital sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 1,552 shares — an estimated $381K sold.

Wedmont Private Capital first reported a position in ABMD in Q1 2022 and held it in 3 quarters. The position peaked at $435K in Q1 2022. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Wedmont Private Capital reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Wedmont Private Capital sold 1,552 Abiomed Inc shares in Q4 2022, an estimated $381K.
  • Wedmont Private Capital first reported a position in Abiomed Inc in Q1 2022 and held it in 3 quarters.
  • Wedmont Private Capital's Abiomed Inc position peaked at $435K in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Wedmont Private Capital's 13F filing for Q4 2022, filed 9 Jan 2023.